NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
Immunicom, Inc. has been awarded $2 million by the National Cancer Institute (NCI) and National Institutes of Health (NIH) to initiate its first US-based clinical trial at the Baylor College of Medicine in Houston, Texas.
[British Journal of Pharmacology] In vivo, investigators studied the role of Caspase-11 in several angiogenesis mouse models using Caspase-11 wild-type and knockout mice. In vitro, scientists detected the effects of Caspase-4 on endothelial functions and Notch signaling by depleting or overexpressing Caspase-4 in HUVECs.
[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified the reversible SUMOylation of FGF receptor 1 (FGFR1) as an intrinsic fine-tuned mechanism in coordinating endothelial angiogenic signaling during neovascularization.